AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent v ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Lumos Pharma Inc. (NYSE: LUMO), relating to its proposed merger with Double Point Ventures LLC. Under the terms of the agreement, Double Point Ventures will acquire Lumos Pharma’s outstan ...

NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed acquisition of the company by Double Point Ventures LLC. Stockholders will receive $4.25 and one contingent value right for each share of Lumos Pharma stock that they hold. The transaction is expected to close by the end of 2024.If you are a stockholder of Lumos Pharma, Inc. and are interested in obtaining additio ...

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluatin ...

Financial Data and Key Metrics Changes - The company ended Q2 2024 with cash, cash equivalents, and short-term investments totaling $16.8 million, down from $36 million on December 31, 2023 [13] - The net loss for Q2 2024 was $7.6 million, compared to a net loss of $8.9 million for the same period in 2023 [15] Business Line Data and Key Metrics Changes - Research and development expenses for the quarter were $4.6 million, a decrease of $1.4 million compared to the same period in 2023, primarily due to decreases in contract manufacturing and personnel-related expenses [14] - General and administrative expenses for the quarter were $3.7 million, a decrease of $0.5 million compared to the same period in 2023 [14] Market Data and Key Metrics Changes - The company is confident in LUM-201's potential as the first oral therapeutic in the expanding $5 billion global growth hormone market [6] Company Strategy and Development Direction - The company is advancing LUM-201 as the first oral therapeutic for moderate pediatric growth hormone deficiency (PGHD) and is preparing for a Phase 3 pivotal trial [4] - The initiation of the Phase 3 trial has been extended to Q2 2025 to allow for the completion of manufacturing a placebo [5] - The company has engaged Piper Sandler to explore strategic opportunities to maximize shareholder value [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trial design and the potential for LUM-201 to transform the growth hormone market, which has been dominated by injectable products for nearly 40 years [16] - The company anticipates exciting developments throughout the year and aims to keep stakeholders informed about progress [16] Other Important Information - The company plans to finalize the design details of the Phase 3 trial in Q4 2024 and expects to secure final agreement with the FDA [11] Q&A Session Summary Question: Enrollment dynamics for the Phase 3 trial - The Chief Medical Officer indicated that the company aims to enroll 150 patients within 15 to 18 months, with interest from physicians and sites already established [18] Question: Strategic opportunities and financing - Management confirmed a focus on PGHD while exploring other indications, emphasizing prudent capital use [19][20] Question: Potential global deals for LUM-201 - Management acknowledged significant interest in global potential and is exploring various strategic opportunities, including potential deals outside the US [22][23] Question: Updates on nonalcoholic fatty liver study - Management noted that the study is progressing and there is potential in the cardiometabolic space [24] Question: Interim reviews and trial updates - Management clarified that no interim reviews are planned for the Phase 3 study to maintain data integrity [27] Question: Budget for the Phase 3 trial - The CFO indicated that approximately $85 million to $100 million will be needed to support operations through 2026, including the Phase 3 trial [32]

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinicalstage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024. "The new analyses of data from our OraGrowtH212 Trial furt ...

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1- 4, 2024. Investor & Media Contact: Poster Session P069 – Monday June 3, 12:00-1:30 PM ET Lisa M ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4200 Marathon Blvd #200 ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended Mar ...

Exhibit 99.1 Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024 at 8:30AM ET AUSTIN, TX, May 14, 2024 (GLOBE NEWSWIRE) – Lumos P ...

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Confe ...